Cronos Group (NASDAQ:CRON – Get Free Report) and Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
Profitability
This table compares Cronos Group and Alaunos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cronos Group | -1.14% | -1.26% | -1.20% |
| Alaunos Therapeutics | N/A | -172.65% | -123.32% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Cronos Group and Alaunos Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cronos Group | 1 | 2 | 2 | 0 | 2.20 |
| Alaunos Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Institutional & Insider Ownership
8.7% of Cronos Group shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 7.8% of Cronos Group shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Cronos Group has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500.
Earnings and Valuation
This table compares Cronos Group and Alaunos Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cronos Group | $146.59 million | 7.01 | -$9.45 million | ($0.01) | -273.00 |
| Alaunos Therapeutics | N/A | N/A | -$4.18 million | ($2.21) | -1.14 |
Alaunos Therapeutics has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cronos Group beats Alaunos Therapeutics on 9 of the 13 factors compared between the two stocks.
About Cronos Group
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.
